To date, a number of proteolytic fragments of tau have already been identified in cerebrospinal fluid (CSF) and plasma from patients with neurodegenerative diseases, supporting their application as biomarkers of disease progression [15]. This evidence concerns the gene MAPT and neurodegenerative disease.